N-[[4-(diaminomethylideneamino)phenyl]methyl]piperazine-1-carboxamide | 178972-27-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-[[4-(diaminomethylideneamino)phenyl]methyl]piperazine-1-carboxamide
• CAS: 178972-27-5
• 化学式: C₁₃H₂₀N₆O
• 分子量: 276.341
• InChiKey: AUPWWDVQKHNVNG-UHFFFAOYSA-N

物化性质

• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  109
• 氢给体数：
  4
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,8-二辛酰氯 、 N-[[4-(diaminomethylideneamino)phenyl]methyl]piperazine-1-carboxamide 生成 N-[[4-(diaminomethylideneamino)phenyl]methyl]-4-[8-[4-[[4-(diaminomethylideneamino)phenyl]methylcarbamoyl]piperazin-1-yl]-8-oxooctanoyl]piperazine-1-carboxamide
  参考文献：
  名称：

  Dibasic inhibitors of human mast cell tryptase. Part 2: Structure–activity relationships and requirements for potent activity

  摘要：

  Detailed structure-activity relationships (SARs) for a series of dibasic human tryptase inhibitors are presented. The structural requirements for potent inhibitory activity are remarkably broad with a range of core template modifications being well tolerated. Optimized inhibitors demonstrate potent anti-asthmatic activity in a sheep model of allergic asthma. APC-2059, a dibasic tryptase inhibitor with subnanomolar activity, has been advanced to phase II clinical trials for the treatment of both psoriasis and ulcerative colitis. (C) 2000 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(00)00485-6
• 作为产物：
  描述：

  在 三氟乙酸 作用下， 生成 N-[[4-(diaminomethylideneamino)phenyl]methyl]piperazine-1-carboxamide
  参考文献：
  名称：

  Dibasic inhibitors of human mast cell tryptase. Part 2: Structure–activity relationships and requirements for potent activity

  摘要：

  Detailed structure-activity relationships (SARs) for a series of dibasic human tryptase inhibitors are presented. The structural requirements for potent inhibitory activity are remarkably broad with a range of core template modifications being well tolerated. Optimized inhibitors demonstrate potent anti-asthmatic activity in a sheep model of allergic asthma. APC-2059, a dibasic tryptase inhibitor with subnanomolar activity, has been advanced to phase II clinical trials for the treatment of both psoriasis and ulcerative colitis. (C) 2000 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(00)00485-6

文献信息

• Dibasic inhibitors of human mast cell tryptase. Part 1: Synthesis and optimization of a novel class of inhibitors
  作者：Kenneth D Rice、Anthony R Gangloff、Elaine Y.-L Kuo、Jeffrey M Dener、Vivian R Wang、Robert Lum、William S Newcomb、Chris Havel、Daun Putnam、Lynne Cregar、Martin Wong、Robert L Warne

  DOI：10.1016/s0960-894x(00)00484-4

  日期：2000.10

  The synthesis and optimization of a novel class of reversible and active-site directed dibasic inhibitors of human mast cell tryptase are described. The compounds were shown to be both remarkably potent and selective for tryptase with Ki values for optimized inhibitors in the picomolar range. (C) 2000 Published by Elsevier Science Ltd.